# EDGAR Filing Document

**Accession Number:** 0001679082
**File Stem:** 0001140361-23-004155
**Filing Date:** 2023-2
**Character Count:** 3749
**Document Hash:** 59b5370fb3b44ceb8a5d8728b7ca3b45
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-23-004155.hdr.sgml**: 20230202

**ACCESSION NUMBER**: 0001140361-23-004155

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230202

**DATE AS OF CHANGE**: 20230202

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Myovant Sciences Ltd.
- **CENTRAL INDEX KEY:** 0001679082
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** CA
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37929
- **FILM NUMBER:** 23580829

**BUSINESS ADDRESS:**
- **STREET 1:** SUITE 1, 3RD FLOOR
- **STREET 2:** 11-12 ST. JAMES SQUARE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** SW1Y 4LB
- **BUSINESS PHONE:** 44 207-400-3351

**MAIL ADDRESS:**
- **STREET 1:** SUITE 1, 3RD FLOOR
- **STREET 2:** 11-12 ST. JAMES SQUARE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** SW1Y 4LB

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549
SCHEDULE 14A INFORMATION

#### Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
**(Amendment No.**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **)**

**** 

<br> ------

Filed by the Registrant ☒&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

☐ Definitive Proxy Statement

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;☒ Definitive Additional Materials

☐ Soliciting Material under § 240.14a-12

## Myovant Sciences Ltd.

#### (Name of Registrant as Specified in Its Charter)
(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;☒ No fee required

☐ Fee paid previously with preliminary materials

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

------

![](image00001.jpg)

February 2, 2023

Dear Shareholder:

We have previously sent you proxy material for the important Special General Meeting of shareholders of Myovant Sciences Ltd. ("Myovant") taking place on March 1, 2023, in connection with a proposal to vote on a merger with Sumitovant Biopharma Ltd (the "Merger Proposal"). **The special committee (the "Special Committee") of the Board of Directors of Myovant (the "Myovant Board") and the Myovant Board (acting upon the unanimous recommendation of the Special Committee) each recommends that you vote FOR the Merger Proposal and related proposals.**

Please note that failing to vote will have the same effect as a vote **AGAINST** the Merger Proposal; therefore, your vote is very important, regardless of the number of shares you own. **If you have not already done so, please vote TODAY *via* the Internet, telephone, or by signing, dating and returning the enclosed proxy card in the envelope provided.**

On behalf of the Myovant Board, thank you for your support.

Very truly yours,

#### David Marek
*Principal Executive Officer and Director*

** 

<br> ***YOUR VOTE IS IMPORTANT—PLEASE VOTE TODAY!***<br>**You can vote your shares *via* the Internet at proxyvote.com.**<br> **Please follow the easy instructions on the enclosed proxy card.**<br>If you have any questions, or need assistance in voting<br> your shares, please call our proxy solicitor:<br>**INNISFREE M&A INCORPORATED**<br> (877) 750-0537 (toll-free from the U.S. and Canada) or<br> **+1 (412) 232-3651 (from other countries)**<br> **** <br>

#### <br>

------